ENZON, Inc. - New Chairman Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ENZON, Inc. - New Chairman

ENZN 0.0400

0.0%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: ocerg who wrote (54)	3/18/1998 7:20:00 PM
From: ocerg	Read Replies (1) of 96

News item on Schering-Plough today says that SP is expecting that a new patent to be issued on Intron A will extend its patent protection another twenty years after its original expiration date in 2001. Peg Intron A was not mentioned in the news release since the patent will issue from the original Intron A formulation not PEG Intron A. Its hard to read what impact, IF ANY, this might have on ENZN. One of the pluses for PEG Intron was the potential that the Intron A could extend its patent life based on the PEG formulation. Does SP need PEG Intron now????? Will the new economics of Intron A (why pay royalties to ENZN)force ENZN to the sidelines?? On the plus side, the formulation benefits of PEG Intron, and there appear to be several, would make PEG Intron A a very formitable force in its market. SP is almost to the finish line with FDA approval for the PEG version. The question now could be will they market it. Any comments??

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next